Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Breast Cancer Reports
Erschienen in: Current Breast Cancer Reports 1/2011

01.03.2011

Epigenetic Therapy in Breast Cancer

verfasst von: Maryam B. Lustberg, Bhuvaneswari Ramaswamy

Erschienen in: Current Breast Cancer Reports | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Breast carcinogenesis is a multistep process involving both genetic and epigenetic changes. Epigenetics is defined as reversible changes in gene expression, not accompanied by alteration in gene sequence. DNA methylation, histone modification, and nucleosome remodeling are the major epigenetic changes that are dysregulated in breast cancer. Several genes involved in proliferation, anti-apoptosis, invasion, and metastasis have been shown to undergo epigenetic changes in breast cancer. Because epigenetic changes are potentially reversible processes, much effort has been directed toward understanding this mechanism with the goal of finding effective therapies that target these changes. Both demethylating agents and the histone deacetylase inhibitors (HDACi) are under investigation as single agents or in combination with other systemic therapies in the treatment of breast cancer. In this review, we discuss the role of epigenetic regulation in breast cancer, in particular focusing on the clinical trials using therapies that modulate epigenetic mechanisms.
Literatur
1.
2.
Maass N, Biallek M, Rosel F, Schem C, Ohike N, Zhang M, Jonat W, Nagasaki K: Hypermethylation and histone deacetylation lead to silencing of the maspin gene in human breast cancer. Biochem Biophys Res Commun 2002, 297(1):125–128.CrossRefPubMed
3.
Stearns V ZQ, Davison NE.: Epigenetic Regulation as a New Target for Breast Cancer Therapy. Cancer Investigation 2007, 25:659–665.CrossRefPubMed
4.
Yan P PM, Laux D, Asare A, Caldwell C, Huang T: CpG Island Arrays: An application toward Deciphering epigenetic signatures of breast cancer. Clinical Cancer Research 2000, 6:1432–1438.PubMed
5.
Portela A, Esteller M: Epigenetic modifications and human disease. Nat Biotechnol, 28(10):1057-1068.
6.
Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007, 8(4):286–298.CrossRefPubMed
7.
Giacinti L, Claudio PP, Lopez M, Giordano A: Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 2006, 11(1):1–8.CrossRefPubMed
8.
Lopez-Serra L, Ballestar E, Ropero S, Setien F, Billard LM, Fraga MF, Lopez-Nieva P, Alaminos M, Guerrero D, Dante R et al.: Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins. Oncogene 2008.
9.
Esteller m: Epigenetics in Cancer. The New England Journal of Medicine 2008, 358:1148–1159.CrossRefPubMed
10.
Elsheikh SE, Green AR, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA et al.: Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 2009, 69(9):3802–3809.CrossRefPubMed
11.
Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K et al.: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005, 37(4):391–400.CrossRefPubMed
12.
Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB et al.: Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 2008, 47(9):701–706.CrossRefPubMed
13.
Harikrishnan KN, Chow MZ, Baker EK, Pal S, Bassal S, Brasacchio D, Wang L, Craig JM, Jones PL, Sif S et al.: Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat Genet 2005, 37(3):254–264.CrossRefPubMed
14.
• Lehmann U, Hasemeier B, Christgen M, Muller M, Romermann D, Langer F, Kreipe H: Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 2008, 214(1):17–24. This is a study of epigenetic regulation of miRs in breast cancer. CrossRefPubMed
15.
Matzke MA, Mette MF, Kanno T, Matzke AJ: Does the intrinsic instability of aneuploid genomes have a causal role in cancer? Trends Genet 2003, 19(5):253–256.CrossRefPubMed
16.
Polyak K, Haviv I, Campbell IG: Co-evolution of tumor cells and their microenvironment. Trends Genet 2009, 25(1):30–38.CrossRefPubMed
17.
Peterson TJ, Karmakar S, Pace MC, Gao T, Smith CL: The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity. Mol Cell Biol 2007, 27(17):5933–5948.CrossRefPubMed
18.
Yang X, Phillps DL, Fergusson AT et al.: Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001, 16:7025–7029.
19.
Zhou Q, Atadja P, Davidson NE: Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther 2007, 6(1):64–69.CrossRefPubMed
20.
Subramanian K, Jia D, Kapoor-Vazirani P, Powell DR, Collins RE, Sharma D, Peng J, Cheng X, Vertino PM: Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol Cell 2008, 30(3):336–347.CrossRefPubMed
21.
Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, Welshons WV, Wei SH, Davuluri RV, Plass C et al.: Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 2004, 64(22):8184–8192.CrossRefPubMed
22.
Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, Baylin SB, Issa JP, Davidson NE: Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 1996, 2(5):805–810.PubMed
23.
Fleury L, Gerus M, Lavigne AC, Richard-Foy H, Bystricky K: Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells. Oncogene 2008.
24.
Badia E, Duchesne MJ, Semlali A, Fuentes M, Giamarchi C, Richard-Foy H, Nicolas JC, Pons M: Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Res 2000, 60(15):4130–4138.PubMed
25.
Terada K, Okochi-Takada E, Akashi-Tanaka S, Miyamoto K, Taniyama K, Tsuda H, Asada K, Kaminishi M, Ushijima T: Association between frequent CpG island methylation and HER2 amplification in human breast cancers. Carcinogenesis 2009, 30(3):466–471.CrossRefPubMed
26.
Fiegl H, Millinger S, Goebel G, Muller-Holzner E, Marth C, Laird PW, Widschwendter M: Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res 2006, 66(1):29–33.CrossRefPubMed
27.
Bali P PM, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang H, Richon V, Bhalla K: Activity of Suberoylanilide Hydroxamic acid against human breast cancer cells with amplificatoin of Her 2. Clinical Cancer Research 2005, 11(17):6382–6389.CrossRefPubMed
28.
Fuino L BP, Wittman S et al.: Histone deacetylse inhibitor LAQ824 down regulated Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone. B Mol Cancer Ther 2003, 2:971–984.
29.
Yang X FA, Nass SJ: Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone decetylase inhibition. Cancer Res 2000, 60:6890–6894.PubMed
30.
Robert MF, Morin S, Beaulieu N et al.: DNMT1 is requiered to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 2003, 33:61–65.CrossRefPubMed
31.
Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, Marquez VE, Greer S, Orntoft TF, Thykjaer T et al.: Preferential response of cancer cells to zebularine. Cancer Cell 2004, 6(2):151–158.CrossRefPubMed
32.
• Stathis A, Hottie S, Hirte, H et al.: Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin’s lymphomas (NHL). J Clin Oncol 2009, 27:15s, (suppl; abstr 3528). This is a phase I study of DNMT inhibitor in combination with HDACi in solid tumors. CrossRef
33.
Arce C, Perez-Plasencia C, Gonzalez-Fierro A, de la Cruz-Hernandez E, Revilla-Vazquez A, Chavez-Blanco A, Trejo-Becerril C, Perez-Cardenas E, Taja-Chayeb L, Bargallo E et al.: A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS ONE [Electronic Resource] 2006, 1:e98.CrossRef
34.
Candelaria M, Gallardo-Rincon D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, Gonzalez-Fierro A, Chavez-Blanco A, de la Cruz-Hernandez E, Camargo MF et al.: A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Annals of Oncology 2007, 18(9):1529–1538.CrossRefPubMed
35.
Isaacs JS, Xu W, Neckers L: Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3(3):213–217.CrossRefPubMed
36.
Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K: Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clinical Cancer Research 2005, 11(17):6382–6389.CrossRefPubMed
37.
Thomas S, Munster PN: Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett 2009, 280(2):184–191.CrossRefPubMed
38.
Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001, 61(23):8492–8497.PubMed
39.
Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, Herger B, Yang Y, Atadja P, Wu J et al.: Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 2007, 13(16):4882–4890.CrossRefPubMed
40.
Bicaku E, Marchion DC, Schmitt ML, Munster PN: Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res 2008, 68(5):1513–1519.CrossRefPubMed
41.
Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN: Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004, 92(2):223–237.CrossRefPubMed
42.
Kelly WK, Richon VM; O’Connor O, et al.: Phase I clinical trial of histone deacetylase inhibitor suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003, 9:3578–3588.PubMed
43.
Kelly WK, O’Connor OA, Krug LM. et al.: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid in patients with advanced cancer. J Clin Oncol 2005, 23:3923–3931.CrossRefPubMed
44.
Luu TH, Morgan RJ, Leong L, et al.: A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium Study. Clinical Cancer Research 2008, 14:7138–7142.CrossRefPubMed
45.
• Munster PN, Lacevic M, Thomas S , Christian C, Ismail-Khan R, Melisko M, Rugo HE and Minton SE. Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy. J Clin Oncol 2009;Vol 27, No 15S (May 20 Supplement): 1075. This is a proof-of-principle study showing the effects of vorinostat in reverting tamoxifen resistance.
46.
A. M. Wardley RS, J. McCaffrey, J. Crown, Z. Malik, D. Rea, P. J. Barrett-Lee, G. T. Lee: Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy J Clin Oncol 2010, J Clin Oncol 28:15s, (suppl; abstr 1052).
47.
• Ramaswamy B BK, Cohen B, et al.: Phase II trial of the histone deacetylase inhibitor (HDACi) vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer (MBC): New York Cancer Consortium Trial 7703. AACR 100th Annual Meeting April 18–22 2009, 09-AB4116-AACR Denver, CO. This is an important study demonstrating the benefits of combining chemotherapy and vorinostat in breast cancer.
48.
Munster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C et al.: Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007, 25(15):1979–1985.CrossRefPubMed
49.
R. Swaby MW, J. Sparano, K. Bhalla, N. Meropol, C. Falkson, C. Pellegrino, P. Klein, L. Goldstein and G. Sledge, Jr: A Phase II Study of the Histone Deacetylase Inhibitor, Vorinostat, in Combination with Trastuzumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent HER-2 Amplified Breast Cancer Resistant to Transtuzumab-Containing Therapy: (E1104) a Trial of the Eastern Cooperative Oncology Group. Cancer Res 2009, 69(24 Suppl):Abstract nr 5084.
50.
Conte P, Campone, M, Pronzato, P, D. Amadori, R. Frank, F. Schuetz, D. Rea, A. Wardley, C. Britten and A. Elias Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability results. Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition)2009, Vol 27, No 15S (May 20 Supplement), 2009: 1081
51.
N. W. Peacock, SF Jones, D. A. Yardley, J. C. Bendell, J. R. Infante, P. B. Murphy, H. A. Burris III: A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib. J Clin Oncol 2010, 28:15s, (suppl; abstr 1115)
52.
Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T, Hartmann O, Kluth A, Dietrich D et al.: DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat 2007.
53.
Fiegl H, Jones A, Hauser-Kronberger C, Hutarew G, Reitsamer R, Jones RL, Dowsett M, Mueller-Holzner E, Windbichler G, Daxenbichler G et al.: Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin Cancer Res 2008, 14(11):3494–3502.CrossRefPubMed
54.
• Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, Stegmaier C, Jacobs IJ, Brenner H: Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS ONE 2008, 3(7):e2656. This article presents the first blood-based study of methylation profiles in breast cancer. CrossRefPubMed
55.
• Radpour R, Kohler C, Haghighi MM, Fan AX, Holzgreve W, Zhong XY: Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene 2009, 28(33):2969–2978. This article reviews a new method for genome-wide methylation studies. CrossRefPubMed
Metadaten
Titel
Epigenetic Therapy in Breast Cancer
verfasst von
Maryam B. Lustberg
Bhuvaneswari Ramaswamy
Publikationsdatum
01.03.2011
Verlag
Current Science Inc.
Erschienen in
Current Breast Cancer Reports / Ausgabe 1/2011
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-010-0034-0

Weitere Artikel der Ausgabe 1/2011

Current Breast Cancer Reports 1/2011 Zur Ausgabe

Clinical Trial Report

Endocrine Therapy Plus Zoledronic Acid in Premenopausal Breast Cancer: Review of a Clinical Trial

ReviewPaper

Targeted Therapies for HER2 Breast Cancer: A View of the Landscape

Clinical Trial Report

Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation: The ALTTO and Neo-ALTTO Trials (Principal Investigators, Martine Piccart-Gebhart and Edith A. Perez)

ReviewPaper

PARP Inhibitors

ReviewPaper

The PI3K/AKT/mTOR Signaling Pathway: Implications in the Treatment of Breast Cancer

ReviewPaper

Insulin-Like Growth Factor Pathway–Targeted Therapy in Breast Cancer

Neu im Fachgebiet Onkologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise